Indication

Hormone receptor positive, HER2-positive metastatic breast cancer

Hormone receptor-positive, HER2-positive metastatic breast cancer is an advanced stage IV malignancy originating in the mammary epithelium that has disseminated beyond the breast and regional lymph nodes to distant organs or tissues. Read more about Hormone receptor positive, HER2-positive metastatic breast cancer

6 drugs 6 manufacturers

Advertisement

Drugs that treat it

Common Hormone receptor positive, HER2-positive metastatic breast cancer therapies.

Showing 1–6 of 6 drugs

Filter & compare in the drug finder →Opens the drug finder with Hormone receptor positive, HER2-positive metastatic breast cancer preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Hormone receptor positive, HER2-positive metastatic breast cancer.

Hormone receptor-positive, HER2-positive metastatic breast cancer is an advanced stage IV malignancy originating in the mammary epithelium that has disseminated beyond the breast and regional lymph nodes to distant organs or tissues.

This distinct molecular subtype is characterized by the co-expression of estrogen and/or progesterone receptors alongside the amplification of the ERBB2 gene or overexpression of the human epidermal growth factor receptor 2 protein.

The dual activation of intracellular steroid hormone signaling and HER2-driven receptor tyrosine kinase pathways produces aggressive cellular proliferation, survival signaling, and complex biological cross-talk that influences therapeutic sensitivity.

Personalize your experience

Follow Hormone receptor positive, HER2-positive metastatic breast cancer and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it